Class summary at a glance.

Every drug in the Recombinant Human Nerve Growth Factor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $1.22Bcombined across class
Total Rx claims: 31K8K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Cenegermin-Bkbj

Brand: OXERVATE · 31K Part D claims (CY24) · 8K beneficiaries · First FDA approval: 2018-11-26

Brand-only (no generics) 54 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $1.22B

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.